Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
151 participants
OBSERVATIONAL
2014-02-11
2021-02-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
IFM2009-02-Pomalidomide and Dexamethasone Phase 2 Myeloma
NCT01053949
Phase II Multicenter, Open-label, Single Arm Clinical Study of Pomalidomide and dexamethasonE and Cyclophosphamide
NCT02046915
A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial (PCD)
NCT02244125
Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
NCT07096778
A Post Authorisation Registry of IMNOVID (Pomalidomide) for Patients With Relapsed and Refractory Multiple Myeloma.
NCT02164955
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pomalidomide following lenalidomide
75 patients with pomalidomide directly following lenalidomide treatment
No interventions assigned to this group
Pomalidomide following other therapy
75 patients with pomalidomide following any other prior therapy. This includes lenalidomide in earlier lines than the most recent line.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adult male and female patients (at least 18 years with no upper age limit)
* Written informed consent to data collection and pseudonymized data transfer
* The conditions of the Pregnancy Prevention Programme must be fulfilled for all patients unless there is reliable evidence that the patient does not have childbearing potential (see summary of product characteristics Imnovid®)
* Other criteria according to summary of product characteristics Imnovid®
Exclusion Criteria
* Pregnant or breast-feeding women
* Male patients, not capable of complying the required preventive measures (see summary of product characteristics Imnovid®)
* Other criteria according to summary of product characteristics Imnovid®
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
iOMEDICO AG
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tobias Dechow, PhD
Role: PRINCIPAL_INVESTIGATOR
practice based oncology office Ravensburg
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
iOMEDICO AG
Freiburg im Breisgau, Baden-Wurttemberg, Germany
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Dechow T, Aldaoud A, Behlendorf T, Knauf W, Eschenburg H, Groschek M, Hansen R, Soling U, Grebhardt S, Siebenbach HU, Vannier C, Potthoff K. Pomalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of the non-interventional study POSEIDON and comparison with the pivotal phase 3 clinical trials. Eur J Haematol. 2022 Feb;108(2):133-144. doi: 10.1111/ejh.13719. Epub 2021 Nov 15.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IOM-10280
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.